In the area of dystonia treatment, we continue to provide botulinum toxin injections to our patients while training physicians to perform these injections. We have conducted a therapeutic trial of transcranial direct current stimulation (tDCS) of the brain in patients with focal hand dystonia, but this was not effective. For patients with blepharospasm, we have been evaluating the efficacy of various types of non-invasive brain stimulation. Low frequency repetitive TMS, theta burst stimulation and tDCS are being compared. We are also conducting a therapeutic trial in blepharospasm of a cream that has an action similar to botulinum toxin. Past studies from our group have shown that certain rehabilitation techniques, such as motor training and sensory training can be therapeutic. We are trying to develop other methods of rehabilitation that might be more efficacious. We are trying to develop non-invasive brain stimulation methods for improvement in Parkinson disease (PD). A past study showed that this could be done with 25 Hz repetitive transcranial magnetic stimulation (rTMS). We have now completed addtional trials of tDCS, intermittent theta burst stimulation (iTBS), and rTMS at 50 Hz. In other studies, we are evaluating a new device to see if it can provide objective evidence of motor deterioration in early PD. New treatments are needed for essential tremor. One promising agent is 1-octanol which we continue to develop. We are currently working to characterize this drugs pharmacokinetics and comparing the efficacy of different formulations in a dose escalation and cross-over study in patients with ET. In addition to characterizing the pharmacokinetics of 1-octanol, we have tested its efficacy in a double-blind placebo-controlled trial in patients with essential tremor. We are currently conducting a trial with 1-octanoic acid, a metabolite of 1-octanol. Other similar agents might also be examined in the future.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2010
Total Cost
$526,079
Indirect Cost
City
State
Country
Zip Code
Jinnah, H A; Comella, Cynthia L; Perlmutter, Joel et al. (2018) Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon 147:89-95
Lin, Peter T; Ross, Erika K; Chidester, Paula et al. (2018) Noninvasive neuromodulation in essential tremor demonstrates relief in a sham-controlled pilot trial. Mov Disord 33:1182-1183
Wagle Shukla, Aparna; Hu, Wei; Legacy, Joseph et al. (2018) Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm. Brain Stimul 11:645-647
Hallett, Mark (2018) Mechanism of action of botulinum neurotoxin: Unexpected consequences. Toxicon 147:73-76
Klein, Max M; Treister, Roi; Raij, Tommi et al. (2016) Reply. Pain 157:1175-6
Vanegas-Arroyave, Nora; Lauro, Peter M; Huang, Ling et al. (2016) Tractography patterns of subthalamic nucleus deep brain stimulation. Brain 139:1200-10
Haubenberger, Dietrich; Abbruzzese, Giovanni; Bain, Peter G et al. (2016) Transducer-based evaluation of tremor. Mov Disord 31:1327-36
Simpson, David M; Hallett, Mark; Ashman, Eric J et al. (2016) Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:1818-26
Voller, Bernhard; Lines, Emily; McCrossin, Gayle et al. (2016) Dose-escalation study of octanoic acid in patients with essential tremor. J Clin Invest 126:1451-7
Rossi, P Justin; Gunduz, Aysegul; Judy, Jack et al. (2016) Proceedings of the Third Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies. Front Neurosci 10:119

Showing the most recent 10 out of 49 publications